Third-line salvage chemotherapy in Hodgkin's disease

G. Bonadonna, S. Viviani, P. Valagussa, V. Bonfante, A. Santoro

Research output: Contribution to journalArticlepeer-review

Abstract

CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.

Original languageEnglish
Pages (from-to)23-25
Number of pages3
JournalSeminars in Oncology
Volume12
Issue number1 SUPPL. 2
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Third-line salvage chemotherapy in Hodgkin's disease'. Together they form a unique fingerprint.

Cite this